More News

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains

The ADEAR Training Program is now accepting applications for post-doctoral training in HIV/AIDS-related research for the 2020-21 academic year.  This integrative program provides multidisciplinary training in basic, translational and clinical science in human immunodeficiency virus type 1 (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research.  Postdoctoral scientist will receive training under the direction of

Congratulations to Schenita Randolph and the entire research team for the AWARD of their proposal to Gilead Sciences, Inc. entitled “A Salon-Based, Multi-level Intervention to Improve PrEP Uptake among Black Women living in the United States South”.  The award is for a 3 year period with a start date of August 1, 2020. 

OVERVIEW AND SPECIFIC AIMS

The U.S.

From the beginning of her career, Dr. Lauren Pacek has been interested in conducting research with vulnerable populations. During her undergraduate program, she volunteered in a professor’s lab where the focus was on smoking cessation. Then, in graduate school, she began working with populations living with HIV. Today, Dr. Pacek is an Assistant Professor in Psychiatry and Behavioral Sciences in Duke’s School of Medicine.

DURHAM, N.C. – Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus.

The finding, led by a team of researchers at the Duke Human Vaccine Institute (DHVI) and Boston Children’s Hospital, publishes online Dec. 5.